Surrozen, Inc. Common earnings per share and revenue
On Nov 07, 2025, SRZN reported earnings of -8.36 USD per share (EPS) for Q3 25, missing the estimate of -1.15 USD, resulting in a -622.12% surprise. Revenue reached 983.00 thousand, compared to an expected --, with a 0.00% difference. The market reacted with a -3.28% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analysts forecast an EPS of -1.18 USD, with revenue projected to reach 510.00 thousand USD, implying an decrease of -85.89% EPS, and decrease of -48.12% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were Surrozen, Inc. Common's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Surrozen, Inc. Common reported EPS of -$8.36, missing estimates by -622.12%, and revenue of $983.00K, 0% as expectations.
How did the market react to Surrozen, Inc. Common's Q3 2025 earnings?
The stock price moved down -3.28%, changed from $12.20 before the earnings release to $11.80 the day after.
When is Surrozen, Inc. Common expected to report next?
The next earning report is scheduled for Mar 30, 2026.
What are the forecasts for Surrozen, Inc. Common's next earnings report?
Based on 4
analysts, Surrozen, Inc. Common is expected to report EPS of -$1.18 and revenue of $510.00K for Q4 2025.